Continuous Petri Nets and microRNA Analysis in Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Personalized targeted therapies are crucial for cancer treatment, but new interventions are needed for aggressive tumors.
• BRAF inhibitors are used for BRAF V600E melanoma, yet some tumors remain resistant.
• Understanding complex signaling pathways is key to improving cancer therapy effectiveness.

Purpose of the Study:

• To simulate and analyze signaling dynamics in BRAF V600E melanoma patients treated with BRAF inhibitors.
• To identify novel therapeutic targets for enhancing standard treatments in aggressive melanoma.
• To investigate the role of microRNAs in melanoma development and treatment response.

Main Methods:

• Development of a continuous Petri Net model to simulate MAPK and PI3K/AKT signaling cascades.
• Analysis of signaling dynamics to predict crucial nodes in melanomagenesis.
• Utilizing the Genomic Data Commons (GDC) Data Portal for clinical data analysis.

Main Results:

• The model identified hsa-mir-132 as a microRNA that downregulates p120RasGAP expression.
• High p120RasGAP levels were shown to decrease MAPK and PI3K/AKT pathway activation.
• Genomic data analysis confirmed a significant association between hsa-mir-132 and clinical outcomes in BRAF-mutated melanoma patients.

Conclusions:

• Targeting microRNAs, such as hsa-mir-132, may enhance the efficacy of BRAF inhibitors in melanoma.
• Antisense oligonucleotides technology presents a potential strategy for miRNA-based cancer therapy.
• This approach could lead to more effective treatments for aggressive and resistant melanoma cases.